CHICAGO — Robert C. Doebele, MD, PhD, associate professor in the division of medical oncology at University of Colorado Anschutz Medical Campus, spoke with…

Several studies designed to investigate immunotherapies and immunotherapeutic combinations for treatment of prostate cancer have yielded encouraging results. …

A phase 2 trial of ruxolitinib met its primary endpoint of overall response rate for the treatment of patients with steroid-refractory graft-versus-host disease…

A trial assessing NBTXR3 plus radiotherapy met its primary endpoint of improved pathologic complete response rate compared with standard of care among patients with soft…